Genital Endometriosis Clinical Trial
Official title:
Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot.
The purpose of this study is to assess rates of administration of add-back therapy in patients with endometriosis in the Russian Federation, during a 6-month course of gonadoliberin agonist leuprorelin 3.75 mg.
This was a non-interventional, observational program in which Lucrin Depot (leuprorelin
acetate) and add-back therapy (hormone and non-hormone) were prescribed in the usual manner
in accordance with the terms of the local marketing authorization with regards to dose,
population and indication (for leuprorelin acetate) and with regards to the local guidelines
or therapeutic recommendation (for add-back therapy).
The rationale for the study was the necessity to characterize the patient population and
long-term leuprorelin acetate administration in the Russian Federation. Further, it was
important to characterize the compliance, tolerability, and safety profile of this therapy
in the routine clinical care setting in the Russian Federation.
;
Time Perspective: Prospective